Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A.

J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.

PMID:
22614995
2.

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte..

Lancet. 2011 Nov 26;378(9806):1858-67. doi: 10.1016/S0140-6736(11)61040-4.

PMID:
22118442
3.

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.

Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, Rosenwald A, Jack A, Sundstrom C, Cogliatti S, Trougouboff P, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Gisselbrecht C.

J Clin Oncol. 2011 Nov 1;29(31):4079-87. doi: 10.1200/JCO.2011.35.4423. Epub 2011 Sep 26.

PMID:
21947824
4.

Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy.

Moore S, Peggs K, Thomson K, Lowry L, Ljubic A, Goldstone AH, Linch DC, Ardeshna KM.

Br J Haematol. 2012 Jan;156(1):142-3. doi: 10.1111/j.1365-2141.2011.08818.x. Epub 2011 Aug 16. No abstract available.

PMID:
21848889
5.

Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy.

Corazzelli G, Frigeri F, Arcamone M, Lucania A, Rosariavilla M, Morelli E, Amore A, Capobianco G, Caronna A, Becchimanzi C, Volzone F, Marcacci G, Russo F, De Filippi R, Mastrullo L, Pinto A.

Br J Haematol. 2011 Sep;154(5):579-89. doi: 10.1111/j.1365-2141.2011.08786.x. Epub 2011 Jun 28.

6.

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.

Micallef IN, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, Perez DG, Soori GS, Link BK, Habermann TM, Witzig TE.

Blood. 2011 Oct 13;118(15):4053-61. doi: 10.1182/blood-2011-02-336990. Epub 2011 Jun 14.

7.

First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.

Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E.

J Clin Oncol. 2011 Jul 10;29(20):2766-72. doi: 10.1200/JCO.2010.31.4187. Epub 2011 Jun 6.

PMID:
21646602
8.

BCL2 and MYC dual-hit lymphoma/leukemia.

Tomita N.

J Clin Exp Hematop. 2011;51(1):7-12. Review.

9.

How I treat primary CNS lymphoma.

Ferreri AJ.

Blood. 2011 Jul 21;118(3):510-22. doi: 10.1182/blood-2011-03-321349. Epub 2011 May 25.

10.

HIV-negative plasmablastic lymphoma: not in the mouth.

Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin GA, Butera JN.

Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):185-9. doi: 10.1016/j.clml.2011.03.008. Epub 2011 Apr 8. Review.

PMID:
21575922
11.

Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse.

Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ.

Haematologica. 2011 Jul;96(7):1002-7. doi: 10.3324/haematol.2011.041277. Epub 2011 Apr 12.

12.

The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective.

Salaverria I, Siebert R.

J Clin Oncol. 2011 May 10;29(14):1835-43. doi: 10.1200/JCO.2010.32.8385. Epub 2011 Apr 11. Review.

PMID:
21482997
13.

Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma.

Eberle FC, Rodriguez-Canales J, Wei L, Hanson JC, Killian JK, Sun HW, Adams LG, Hewitt SM, Wilson WH, Pittaluga S, Meltzer PS, Staudt LM, Emmert-Buck MR, Jaffe ES.

Haematologica. 2011 Apr;96(4):558-66. doi: 10.3324/haematol.2010.033167.

14.

Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.

Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM, Gascoyne RD.

J Clin Oncol. 2011 Apr 10;29(11):1452-7. doi: 10.1200/JCO.2010.33.3419. Epub 2011 Mar 7.

PMID:
21383296
15.

Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry.

van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP, Buzyn A, Boogaerts MA, Luan JJ, Maury S, Milpied NJ, Jouet JP, Ossenkoppele GJ, Sureda A.

J Clin Oncol. 2011 Apr 1;29(10):1342-8. doi: 10.1200/JCO.2010.30.2596. Epub 2011 Feb 14.

PMID:
21321299
16.

Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas.

Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, Jäger E.

Ann Oncol. 2011 Aug;22(8):1839-44. doi: 10.1093/annonc/mdq671. Epub 2011 Jan 21.

PMID:
21257672
17.

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.

Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM, Lacasce A, Morrison J, Elstrom R, Ely S, Chadburn A, Cesarman E, Coleman M, Leonard JP.

J Clin Oncol. 2011 Feb 20;29(6):690-7. doi: 10.1200/JCO.2010.31.1142. Epub 2010 Dec 28.

PMID:
21189393
18.

Two cases of mediastinal gray zone lymphoma.

Minami J, Dobashi N, Asai O, Yano S, Osawa H, Takei Y, Yahagi Y, Takahara S, Ogasawara Y, Yamaguchi Y, Kobayashi T, Morikawa N, Nikaido T, Aiba K, Usui N.

J Clin Exp Hematop. 2010;50(2):143-9.

19.

Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.

Maruyama D, Watanabe T, Maeshima AM, Nomoto J, Taniguchi H, Azuma T, Mori M, Munakata W, Kim SW, Kobayashi Y, Matsuno Y, Tobinai K.

Int J Hematol. 2010 Dec;92(5):732-43. doi: 10.1007/s12185-010-0728-0. Epub 2010 Dec 1.

PMID:
21120644
20.

Double-hit B-cell lymphomas.

Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, Kluin PM.

Blood. 2011 Feb 24;117(8):2319-31. doi: 10.1182/blood-2010-09-297879. Epub 2010 Nov 30. Review.

Supplemental Content

Support Center